Here’s ICX-TRC’s new website:
http://www.intercytex.com/icx/products/aesthetic/icxtrc/
Not much additional information than from PDFs, but here’s how they compare HM to HT:
“The ICX-TRC procedure is significantly less problematic than conventional hair transplants. In terms of the amount of tissue taken from the patient, only a small sample of approximately 120 follicles is needed. As a consequence, trauma suffered by the patient during the procedure may be dramatically reduced. Furthermore, as dermal papilla (DP)cells can be derived from a very small area of hair-bearing scalp, a much higher population of patients will be able to benefit from ICX-TRC than conventional transplantation. Superficial injection of cultured cells into the scalp causes far less tissue damage than implanting multiple hair follicles and is a considerably simpler, shorter and less painful process.”
Also here’s some info on their manufacturing process:
“Intercytex will manufacture ICX-TRC for Europe and the US from its own manufacturing facilities. In October 2006, Intercytex was awarded a grant from the DTI to develop a robotic system with The Automation Partnership for the commercial scale production of patients’ autologous DP cells. The robotic system has an established track record in processing many different cell samples simultaneously, so that at this scale, in which large numbers of different patients’ cells are handled, all samples remain isolated throughout the multiplication process.”